Local and systemic control of Ewing's bone sarcoma family tumors of the ribs
β Scribed by Antonio Briccoli; Michele Rocca; Mariacristina Salone; Emanuela Palmerini; Alba Balladelli; Cristina Ferrari; Maria Di Fiore; Gaetano Bacci
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 105 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Background
A retrospective analysis of the results and relapse pattern was evaluated in 34 patients with Ewing's family bone tumors (EFBT) treated at Rizzoli Institute with neoadjuvant chemotherapy between 1983 and 2003.
Objectives
The aim of the study was to evaluate treatment strategy and compare our results with those obtained in other studies.
Methods
Local treatment in these patients was radiotherapy alone in 4 cases, surgery alone in 13 and surgery followed by radiotherapy in 17.
Results
Fiveβyear eventβfree survival (EFS) was 44%, no different from that observed in another 558 patients with EFBT located in other sites treated in the same period with neoadjuvant chemotherapy protocols. Eighteen patients had a systemic relapse, followed by local relapse in two and one patient had a local relapse alone. EFS was significantly correlated to the time interval between onset symptoms and beginning of treatment and, in operated patients to histologic response to preoperative treatment.
Conclusions
We conclude that EFBT of the ribs, when treated with neoadjuvant chemotherapy, have an outcome similar to that of patients with EFBT located in other sites. J. Surg. Oncol. 2009;100:222β226. Β© 2009 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Abstract ## Background The Ewing sarcoma family of tumors (ESFT) comprises a group of wellβcharacterized neoplasms with aggressive behavior. Despite significant progress with the use of intensive multiagent chemotherapy and local control measures, a significant proportion of patients die of dis
This study was conducted to determine the feasibility of, and improve outcome by, incorporating ifosfamide and etoposide (IE) into the therapy of newly diagnosed patients with Ewing's sarcoma family of tumors of bone and soft tissue. ## METHODS. Fifty-four newly diagnosed patients received 7 cycle